TROP2 expression measured by QCS is a promising predictor of clinical outcomes in patients with mNSCLC

Share :
Published: 26 Sep 2024
Views: 25
Rating:
Save
Dr Marina Garassino - University of Chicago, Chicago, USA

Dr Marina Garassino speaks to ecancer about the TROPION-Lung 01 study presented at WCLC 2024.

The latest data from this study indicates that measuring TROP2 expression using quantitative continuous scoring can help predict clinical outcomes for patients with advanced or metastatic non-small cell lung cancer who are being treated with the TROP2 antibody-drug conjugate datopotamab deruxtecan.

The data revealed that patients testing positive for TROP2 showed better response to datopotamab deruxtecan compared to those receiving docetaxel in the TROPION-Lung01 phase III trial.

Read the full story here.